Research Paper Volume 11, Issue 17 pp 7187—7196

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway

Figure 4. Combined AZ628 and BP-1-102 blocked MEK/ERK signaling pathway. (A) Western blot determined the protein levels of p-MEK and p-ERK in H838 and KRAS(G12D) cells treated with BP-1-102 alone. (B) Western blot determined the protein levels of p-MEK and p-ERK in KRAS(G12S) H292 and KRAS(G12V) H441 cells, as well as KRAS(WT) H661and H1650 cells treated with BP-1-102 alone. (C) Western blot determined the protein levels of p-MEK and p-ERK in KRAS(WT) H838 and KRAS(G12D) H838 cells treated with AZ628 and BP-1-102combination drugs. (D) Western blot determined the protein levels of p-MEK and p-ERK in KRAS(G12S) H292 and KRAS(G12V) H441 cells treated with AZ628 and BP-1-102combination drugs.